新华社成都5月25日电（记者康锦谦、董小红、李倩薇）第二十届中国西部国际博览会（西博会）25日在成都开幕，共吸引包括境外62个国家 （地区）在内的3000余家企业参展，将持续至29日。来自世界各地琳琅满目的商品及各种高精尖技术广受参展客商青睐。 本届西博会首设"一欧一亚"双主宾国。记者在主宾国老挝的展馆看到，馆内特别设置了生态产品展示区，集中呈现茶叶、咖啡、啤酒、大米 等特色农产品及木制工艺品、家具等，前来问询的客人络绎不绝。现场还有老挝古树茶品鉴区域，洽谈生意的客人可以品鉴来自热带雨林的独特 风味。 "西博会为包括老挝在内的各国企业提供了宝贵的商贸对接、投资合作和信息共享机遇，有力促进了区域商品市场的互联与互通。"老挝副总 理吉乔在开幕式致辞中说。 "中国西部在可再生能源、先进制造业、物流领域蕴藏着巨大潜力，为世界各地企业和投资者带来了巨大商机，我们鼓励更多企业积极投身这 片充满活力的热土，借助西博会这一优质平台建立起长久稳定的合作关系。"瓦努阿图副总理兼财长科纳坡在开幕式上说。 参展客商普遍看好中国西部市场前景。77电子集团是一家来自匈牙利的体外诊断医疗设备开发商，总经理李察德说，匈牙利人口不到1000万 ...

截至2025年5月23日收盘，三星医疗（601567）报收于23.83元，较上周的24.95元下跌4.49%。本周，三 星医疗5月19日盘中最高价报24.93元。5月22日盘中最低价报23.65元，股价触及近一年最低点。三星医 疗当前最新总市值336.24亿元，在电网设备板块市值排名6/120，在两市A股市值排名404/5148。 本周关注点 公司公告汇总 三星医疗关于2024年核心团队持股计划锁定期届满的提示性公告显示，根据相关规定，公司2024年核心 团队持股计划将于2025年5月22日锁定期届满，且公司层面第一个归属考核期业绩指标已达成。2024年5 月23日，2048590股公司股票过户至持股计划证券账户，过户价格为20.58元/股。2025年5月14日，公司 审议通过业绩指标达成的议案，第一个归属考核期可归属本次核心团队持股计划的60%。 三星医疗关于完成工商变更登记的公告指出，公司已完成工商变更登记手续，并取得宁波市市场监督管 理局换发的营业执照。变更后的注册资本为1,411,085,871元，法定代表人为沈国英，经营范围涵盖投资 活动、医院管理、工程管理服务、仪器仪表制造与销售等多个领域。 以上 ...

Group 1 - China Communication Technology Co., Ltd. won a total of 11 important rail transit projects with a total bid amount of approximately 3.789 billion yuan, accounting for 11.67% of the company's audited revenue for 2024 [1] - New Chai Co., Ltd. plans to use no more than 500 million yuan of idle funds to purchase low-risk financial products to improve fund efficiency [2] - Qingshan Paper Industry's controlling shareholder intends to restructure and inject assets into Fujian Provincial Industrial Holding Group [3] Group 2 - BWS hired Liu Xiaodan as Senior Vice President, effective immediately [4] - Huakang Clean won a bid for a purification project at the Tengzhou Medical and Health Center, with a bid price of 60.2394 million yuan [6] - Silver Dragon Co., Ltd. announced that several executives plan to reduce their holdings by a total of no more than 550,000 shares due to personal financial needs [8] Group 3 - Intercontinental Oil & Gas plans to invest 848 million USD in the South Basra Integrated Project in Iraq, holding a 67% stake [13] - Huatai Dain's subsidiary received a drug registration certificate for sodium valproate oral solution, used for treating epilepsy [14] - Hainan Mining's 20,000-ton battery-grade lithium hydroxide project has achieved full-process connectivity and produced qualified products [29] Group 4 - Roman Co., Ltd.'s subsidiary won a significant overseas project in Saudi Arabia with a bid amount of approximately 200 million yuan [30] - Measurement Co., Ltd. completed a capital reduction for its subsidiary, optimizing resource allocation [31] - Guodian Nanzi plans to increase capital by 45 million yuan for its wholly-owned subsidiary to meet market expansion needs [32] Group 5 - Eighty Billion Space plans to repurchase shares with a total amount not less than 50 million yuan and not exceeding 100 million yuan [33] - Tianyin Electromechanical's director plans to reduce holdings of no more than 0.25% of the company's shares [34] - Hailier's subsidiary passed environmental protection acceptance for its agricultural chemical preparation project [35] Group 6 - Kelong Pharmaceutical's subsidiary will present innovative drug research results at the ASCO annual meeting [36] - Zhonghong Medical's subsidiary received medical device registration certificates for enteral nutrition pumps and injection pumps [37] - Luyou Pharmaceutical received a drug registration certificate for amlodipine besylate tablets, used for hypertension [39]

证券代码：601567 证券简称：三星医疗 公告编号：临 2025-041 宁波三星医疗电气股份有限公司 关于完成工商变更登记的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 宁波三星医疗电气股份有限公司（以下简称"公司"）于 2025 年 1 月 10 日 召开第六届董事会第二十次会议，审议通过了《关于公司变更注册资本、修订< 公司章程>并办理工商变更登记的议案》。具体详见公司于 2025 年 1 月 11 日披露 于上海证券交易所网站（www.sse.com.cn）、中国证券报、上海证券报和证券时 报的《宁波三星医疗电气股份有限公司关于公司变更注册资本并修订公司章程的 公告》（公告编号：临 2025-008）。 近日，公司完成了上述事宜的工商变更登记手续，并取得了宁波市市场监督 管理局换发的《营业执照》。工商登记变更后，相关登记信息如下： 公司名称：宁波三星医疗电气股份有限公司 统一社会信用代码：9133020079603386X0 住所：浙江省宁波市鄞州工业园区（宁波市鄞州区姜山镇） 法定代表人：沈国英 注册资本： ...

Core Viewpoint - The innovation drug sector in A-shares and Hong Kong stocks is experiencing significant growth, driven by strong performance in related ETFs and positive market sentiment towards Chinese pharmaceutical companies [1][2][3] Group 1: Market Performance - The innovation drug ETF Tianhong (517380) saw an increase of over 2.5% at one point, closing with a nearly 1.7% rise, with key stocks like Ascentage Pharma-B rising over 6% [1] - Other related ETFs, such as the medical device ETF (159873) and the biopharmaceutical ETF (159859), also showed positive performance, with the latter achieving a trading volume exceeding 55 million yuan [1][2] Group 2: Company Developments - Heng Rui Pharmaceutical plans to issue 225 million shares in Hong Kong, with its stock price surging over 33% during trading [2] - The innovation drug ETF Tianhong (517380) closely tracks the Hang Seng Shanghai-Shenzhen Hong Kong Innovation Drug 50 Index, which selects 50 leading innovative drug companies, including Heng Rui Pharmaceutical and BeiGene [2] Group 3: Industry Insights - Current market conditions suggest that the Hong Kong innovation drug sector is poised for excess returns due to the global competitive advantages of Chinese pharmaceutical companies [3] - The rise of the NewCo model has helped original drug companies address challenges related to financing, monetization, and research and development risks [3] - Recent policy shifts indicate a favorable regulatory environment for the sector, with signs of support for innovative drugs and optimization of procurement rules [3] - Financially, leading Hong Kong innovative drug companies are benefiting from increased license-out transactions, resulting in steady revenue and profit growth, while valuations remain at relatively safe levels compared to other growth sectors [3]

Nano-X Imaging (NNOX) Q1 2025 Earnings Call May 22, 2025 08:30 AM ET Company Participants Mike Cavanaugh - Managing DirectorErez Meltzer - CEO & Acting Chairman of the BoardRan Daniel - Chief Financial OfficerJeffrey Cohen - MD - Equity Research Conference Call Participants Ross Osborn - Director, Lead Research Analyst - MedTech and DiagnosticsScott Henry - Managing Director & Senior Research Analyst Operator Good day, and thank you for standing by. Welcome to the Nano QX Q1 twenty twenty five Earnings Conf ...

Financial Data and Key Metrics Changes - The company reported a GAAP net loss of $13.2 million for Q1 2025, compared to a net loss of $12.2 million in Q1 2024, reflecting an increase of $1 million largely due to a $1.1 million increase in gross loss [27] - Revenue for Q1 2025 was $2.8 million, with a gross loss of $3 million, compared to revenue of $2.6 million and a gross loss of $2.1 million in the same period last year [27][28] - Non-GAAP gross loss for Q1 2025 was $400,000, down from a gross profit of $600,000 in Q1 2024, indicating a gross margin of approximately 15% for the reported period [28] Business Line Data and Key Metrics Changes - Revenue from teleradiology services for Q1 2025 was $2.6 million, with a gross profit of $400,000, compared to $2.4 million and a gross profit of $300,000 in Q1 2024, representing a gross profit margin of approximately 17% [28] - Revenue from imaging systems and OEM services was $33,000 with a gross loss of $1.6 million in Q1 2025, compared to revenue of $47,000 and a gross loss of $400,000 in the same period last year [29] - Revenue from AI solutions was $200,000 with a gross loss of $1.9 million in Q1 2025, compared to $100,000 and a gross loss of $2 million in Q1 2024 [29] Market Data and Key Metrics Changes - The sales pipeline has doubled since January 2025, with the sales team handling over 1,000 leads, primarily from small and medium-sized health clinics in various countries [9] - The company is targeting over 100 ARC systems in various stages of deployment by the end of 2025, with over 60 units currently in various stages of implementation [10][11] Company Strategy and Development Direction - The company aims to improve medical imaging and enhance patient outcomes through strategic acquisitions and the integration of AI-powered imaging analysis [6][7] - The focus is on expanding the commercialization of Nanox ARC and AI solutions, with a multi-pronged strategy involving direct sales, collaborations, and distributor engagements [8][12] - The company is also pursuing opportunities in the workers' compensation segment, which presents a significant potential market [14] Management's Comments on Operating Environment and Future Outlook - Management acknowledged recent market uncertainties but expressed optimism about the growing base of early adopters for Nanox ARC [11] - The company expects its AI business to break even by 2026 and the ARC business to reach breakeven by 2027, with an anticipated inflection point in the second half of 2025 [57][58] Other Important Information - The company has received FDA clearance for the Nanox Arc X, enhancing its regulatory standing [20] - The company is actively engaged in clinical trials to generate data supporting the use of Nanox Arc, which is crucial for future growth [21] Q&A Session Summary Question: Can you provide details on the fleet deployment by the end of the year? - Management indicated that the majority of units will be in the US, with about 15-20% in Europe and 10% in other regions, depending on regulatory approvals [38] Question: What is the pricing and reimbursement status for the second opinion services? - The second opinion service is priced at approximately $300 and is primarily a retail model, with growing business potential [42] Question: How many units are currently deployed and operational in the US? - More than 20 units are currently installed, with some awaiting regulatory approvals [47] Question: What is the timeline for reaching breakeven across business lines? - The teleradiology division is already profitable, while the AI business is expected to break even in 2026 and the ARC business in 2027 [56][57]

在全球化浪潮的推动下，深圳证券交易所市场(以下简称"深市")上市公司正以创新为桨、实力为帆，积 极拓展海外市场，谱写国际化发展的新篇章。2024年，深市公司实现海外收入4.18万亿元，同比增长 11.62%。 行业龙头企业海外销售持续增长。立讯精密（002475）工业股份有限公司(以下简称"立讯精密")、比亚 迪（002594）股份有限公司(以下简称"比亚迪")、美的集团（000333）股份有限公司(以下简称"美的集 团")、潍柴动力（000338）股份有限公司(以下简称"潍柴动力")、宁德时代（300750）新能源科技股份 有限公司(以下简称"宁德时代")5家公司2024年海外业务收入超千亿元，分别为2354.67亿元、2218.85亿 元、1690.34亿元、1197.74亿元、1103.36亿元。出口导向型公司业绩进一步增长，2024年相关公司营业 收入合计1.78万亿元，同比增长14.6%，净利润合计1229.96亿元，同比增长26.36%。 业内人士认为，从智能制造到数字经济，从绿色能源到消费升级，深市企业正将"中国智造"的品牌魅力 辐射世界，为全球产业链注入新动能。 出海步伐加快 实现全球产业链协 ...

四川港通医疗设备集团股份有限公司 第一章 总 则 第一条 为加强四川港通医疗设备集团股份有限公司（以下简称"公司"或"本 公司"）与投资者及潜在投资者（以下统称"投资者"）之间的信息沟通，切实保护投 资者特别是社会公众投资者的合法权益，促进公司与投资者之间建立长期、稳定的良 性关系，根据《中华人民共和国公司法》 《中华人民共和国证券法》等法律、法规以 及《上市公司投资者关系管理工作指引》 （以下简称"工作指引"）、 《四川港通医疗设 备集团股份有限公司章程》 （以下简称"《公司章程》"）的有关规定，结合本公司实际 情况，制定本制度。 第二条 投资者关系管理是指公司通过便利股东权利行使、信息披露、互动交流 和诉求处理等工作，加强与投资者及潜在投资者之间的沟通，增进投资者对上市公司 的了解和认同，以提升上市公司治理水平和企业整体价值，实现尊重投资者、回报投 资者、保护投资者目的的相关活动。 第二章 投资者关系管理的原则与目的 第三条 投资者关系管理的基本原则： (一) 合规性原则。公司投资者关系管理应当在依法履行信息披露义务的基础 上开展，符合法律、法规、规章及规范性文件、行业规范和自律规则、公司内部规章 制度， ...

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 四川港通医疗设备集团股份有限公司（以下简称"公司"）第四届董事会任 期将于 2025 年 6 月 11 日届满。根据《公司法》《证券法》《深圳证券交易所创 业板股票上市规则》《深圳证券交易所上市公司自律监管指引第 2 号——创业板 上市公司规范运作》等法律法规、规范性文件及《公司章程》的有关规定，公司 按照相关法定程序进行董事会的换届选举工作，现将有关情况公告如下： 公司于 2025 年 5 月 21 日召开的第四届董事会第二十次会议，审议通过了 《关于董事会换届选举暨提名第五届董事会非独立董事候选人的议案》和《关于 董事会换届选举暨提名第五届董事会独立董事候选人的议案》。经公司董事会提 名委员会资格审核，董事会提名陈永先生、陈兴根先生、文再敏先生、陈叙先生 及刘煜强先生为公司第五届董事会非独立董事候选人；提名周正女士、赵尘女士、 姚刚先生为公司第五届董事会独立董事候选人（上述候选人简历详见附件）。 上述董事候选人人数符合相关法律法规、规范性文件及《公司章程》的有关 规定，其中独立董事候选人数的比例不低于董事会成 ...